ArticleFrontiers in immunology2022

Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.

Antti Nätynki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.